Skip to main content
Fig. 1 | BMC Cancer

Fig. 1

From: Identification and characterization of stromal-like cells with CD207+/low CD1a+/low phenotype derived from histiocytic lesions – a perspective in vitro model for drug testing

Fig. 1

The experimental design and aims of the research. Three primary cell lines were obtained from patients with histiocytoses, i.e. RAB-1, HAN-1 and CHR-1. The cells share cytophysiological features of stromal cells with the phenotype of histiocytes progenitors (sl-pHCs). Their proliferative and metabolic activity was determined, including profiling the expression of transcripts and proteins associated with histiocytoses progression. The sl-pHCs were also used to test the cytotoxicity of vemurafenib and trametinib. Obtained and characterized cell lines present a valuable tool for further studies for

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us